BE640616A - - Google Patents

Info

Publication number
BE640616A
BE640616A BE640616DA BE640616A BE 640616 A BE640616 A BE 640616A BE 640616D A BE640616D A BE 640616DA BE 640616 A BE640616 A BE 640616A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of BE640616A publication Critical patent/BE640616A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE640616D 1962-12-19 BE640616A (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US245681A US3119742A (en) 1962-12-19 1962-12-19 Method of preparing sustained release pharmaceutical pellets and product thereof

Publications (1)

Publication Number Publication Date
BE640616A true BE640616A (OSRAM)

Family

ID=22927638

Family Applications (1)

Application Number Title Priority Date Filing Date
BE640616D BE640616A (OSRAM) 1962-12-19

Country Status (5)

Country Link
US (1) US3119742A (OSRAM)
BE (1) BE640616A (OSRAM)
GB (1) GB1030127A (OSRAM)
IT (1) IT983055B (OSRAM)
SE (1) SE328670B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
CA1279574C (en) * 1985-04-17 1991-01-29 Jeffrey L. Finnan Process for lubricating water-soluble vitamin powders
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
SE8701479L (sv) * 1987-04-09 1988-10-10 Carbomatrix Ab Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
FI77573C (fi) * 1987-05-08 1989-04-10 Orion Yhtymae Oy Ny konsistens.
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5328697A (en) * 1992-02-10 1994-07-12 Mallinckrodt Veterinary, Inc. Compositions and processes for the sustained release of drugs
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001072728A2 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Novel piperazine derivatives
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1326867A2 (en) * 2000-10-19 2003-07-16 Pfizer Products Inc. Bridged piperazine derivatives
CZ20033455A3 (en) 2001-06-20 2004-06-16 Pfizer Products Inc. Novel sulfonic acid derivatives
CN1575283A (zh) * 2001-10-22 2005-02-02 辉瑞产品公司 具有ccr1受体拮抗剂活性的哌嗪衍生物
WO2003095439A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Methods for manufacture of dihydro-furan-2-one derivatives
JP2005530775A (ja) * 2002-05-14 2005-10-13 ファイザー・プロダクツ・インク ジヒドロキシヘキサン酸誘導体、それらの中間体、および製法
PA8575901A1 (es) * 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
AP2005003226A0 (en) * 2002-08-12 2005-03-31 Pfizer Prod Inc Crystal forms of quinoxaline-2-carboxylic acid[4-carbamoyl-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide.
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
JP2006508976A (ja) * 2002-11-21 2006-03-16 ファイザー・プロダクツ・インク ３−アミノ−ピペラジン誘導体及び製造法
BR0316487A (pt) * 2002-11-26 2005-10-11 Pfizer Prod Inc Método todo de tratamento da rejeição de transplantes
WO2004055031A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Phosphorus-containing piperazine derivatives as ccr1 antagonists
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
EP1601672B1 (en) * 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
BRPI0408251A (pt) * 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
JP2007512316A (ja) * 2003-11-25 2007-05-17 ファイザー・プロダクツ・インク アテローム性動脈硬化症の治療方法
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
US8461102B2 (en) * 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
KR20210094672A (ko) 2011-05-16 2021-07-29 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014160401A1 (en) 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
JP2016539927A (ja) 2013-10-24 2016-12-22 アッヴィ・インコーポレイテッド Ｊａｋ１選択的阻害剤とその使用
US10065937B2 (en) 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
SG11201802990RA (en) 2015-10-16 2018-05-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7039579B2 (ja) 2016-07-08 2022-03-22 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 抗癌剤としての４－アニリノ－キノリン化合物
WO2019134969A1 (en) 2018-01-05 2019-07-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivates for use in the treatment of lymphomas and leukemia
CN118994103A (zh) 2018-10-03 2024-11-22 特沙诺有限公司 尼拉帕利盐
CN113330007A (zh) 2018-10-03 2021-08-31 特沙诺有限公司 尼拉帕利游离碱的晶体形式
ES3040555T3 (en) 2019-02-04 2025-11-03 Genzyme Corp Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
IL285304B2 (en) 2019-02-04 2025-10-01 Genzyme Corp Methods for treating symptoms and disorders associated with lysosomal storage diseases
EP4100009A1 (en) 2020-02-03 2022-12-14 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
WO2022018695A1 (en) 2020-07-24 2022-01-27 Genzyme Corporation Pharmaceutical compositions comprising venglustat
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022140528A1 (en) 2020-12-23 2022-06-30 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2023196640A1 (en) 2022-04-08 2023-10-12 Bioverativ Therapeutics Inc. Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
KR20250106321A (ko) 2022-12-01 2025-07-09 젠자임 코포레이션 강력하거나 중간 수준인 cyp3a4 억제제와 조합한 벤글루스타트
WO2025074120A1 (en) 2023-10-06 2025-04-10 Imperial College Innovations Limited Nanoparticles for extended release drug delivery
WO2025262570A1 (en) 2024-06-17 2025-12-26 Genzyme Corporation Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments

Also Published As

Publication number Publication date
SE328670B (OSRAM) 1970-09-21
IT983055B (it) 1974-10-31
US3119742A (en) 1964-01-28
DE1492128A1 (de) 1969-08-07
GB1030127A (en) 1966-05-18

Similar Documents

Publication Publication Date Title
BE628990A (OSRAM)
BE626524A (OSRAM)
BE635094A (OSRAM)
BE632502A (OSRAM)
SE328670B (OSRAM)
BE630317A (OSRAM)
BE630311A (OSRAM)
BE630163A (OSRAM)
BE634112A (OSRAM)
BE633821A (OSRAM)
BE632586A (OSRAM)
BE632939A (OSRAM)
BE629958A (OSRAM)
BE629689A (OSRAM)
BE629672A (OSRAM)
BE632501A (OSRAM)
BE630733A (OSRAM)
BE632084A (OSRAM)
BE633448A (OSRAM)
BE629625A (OSRAM)
BE633486A (OSRAM)
BE631987A (OSRAM)
BE631495A (OSRAM)
BE633564A (OSRAM)
BE633999A (OSRAM)